(This April 28 story corrects the fifth paragraph to say that two, not one, other diabetes drugs have positive cardiovascular side-effects) COPENHAGEN (Reuters) – Novo Nordisk said on Thursday a late-stage trial showed its new once-weekly diabetes drug significantly reduced patients’ cardiovascular risks, boosting the company’s hopes of maintaining its lead in the fast-growing diabetes market. The trial, dubbed SUSTAIN 6, showed the drug – called semaglutide – delivered a “statistically significant reduction in cardiovascular risk” compared with placebo in patients with type 2 diabetes. Cardiovascular risks are often higher among diabetes patients because they tend to be overweight.
